On February 28, 2022, the Patent Trial and Appeal Board (“PTAB”) issued a decision on priority in an interference proceeding between the Broad Institute, Inc., Massachusetts Institute of Technology, and President and Fellows of Harvard College (collectively, “Broad”) and the Regents of the University of California, University of Vienna, and Emmanuelle Charpentier (collectively, “CVC”), and held that Broad’s inventors were the first to invent the subject matter of Count 1 of the interference,[1] a CRISPR-Cas9 system with a single guide RNA able to cleave or edit DNA to affect gene expression in a eukaryotic cell. The Regents of the University of California v. The Broad Institute, Inc., Interference No. 106,115, Decision on Priority at 2, 4 (PTAB Feb. 28, 2022).